TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Jul 25, 2022 10:00 JST
Source:
Novotech Health Holdings Pte Ltd
Novotech's Flexible Work Policy is Finalist in Best Workplace Flexibility Program "Excellence Award 2022"
SYDNEY, AU, Jul 25, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO with expanded services in the US, has been recognised for its innovative approach to workplace flexibility.
Novotech CEO Dr. John Moller said: "Our flexible workplace design, information technology infrastructure, and flexible resourcing of projects are consistently delivering successful outcomes for our team members, clients, and all stakeholders. We are extremely pleased our workplace flexibility efforts are recognised by the Best Workplace Flexibility Program which has selected Novotech as an Excellence Awardee in 2022."
Novotech Chief People Officer Angela Edwardson said that "over the last 12 months, Novotech has re-imagined what flexible working looks like for teams, clients, and the business. This renewed way of working incorporates flexible, remote, and in-office working options and aims to create a dynamic business environment and trusted culture. Team members can determine and apply the most effective way to work, unlocking the maximum value of their talent to benefit all stakeholders."
Some of the new flexible working policies include:
- FlexLocation: Work from home, office or other suitable location.
- FlexTime: Flexible start/finish times
- FlexBreak:Bbreaks during the day for wellbeing or other commitments.
- FlexHours: An adjustment to contracted hours, either permanently or temporarily (ie: full-time to part-time).
- FlexPlace: The option to work at other Novotech offices or cities/countries without a Novotech office temporarily.
- FlexStudy: A combination of Flex options and/or leave to meet study commitments.
- FlexHolidays: The option to select alternate dates in lieu of allocated celebration/public holidays.
- FlexLeave: Leave can be taken by the hour and in combination with other leave types and flexible options.
- FlexTimeout: Extended unpaid leave to pursue and interest, relax or attend to caring responsibilities
- FlexPersonal: A combination of day-to-day and/or planned options.
"Already 17 team members have used or are planning to use FlexPlace in 2022," said Edwardson. "Novotech has a large cohort of expatriate workers, and our new addition of FlexPlace supports them to re-connect with their families and friends or travel while still meeting their working requirements."
Novotech's Asia-Pacific and US teams support cost-effective expedited clinical research with world-class data and the most advanced technology including solutions that enable acceleration of clinical trials across the regions.
Novotech now has a workforce of ~2,500 clinical trial professionals across Australia, South Korea, Greater China, Southeast Asia, India, South Africa and the US.
Asia-Pacific offers a compelling solution for expedited clinical trials especially in oncology with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition regulatory reforms, such as those in China, have accelerated approval processes.
The expansion into the US provides US-based expertise and infrastructure for our US clients wanting trials in APAC and the US, and for our APAC clients wanting US clinical programs.
About Novotech
Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit
https://novotech-cro.com/contact
Media Contact
David James
E:
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Source: Novotech Health Holdings Pte Ltd
Sectors: BioTech, Healthcare & Pharm, Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
February 15 2023 09:00 JST
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
February 10 2023 19:00 JST
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
February 03 2023 13:00 JST
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
January 12 2023 15:00 JST
Novotech Acquires European CRO, Strengthens Global Operations
January 12 2023 15:00 JST
Novotech is Gold Sponsor at Biotech Showcase 2023
December 20 2022 11:00 JST
Data Shows 50% of New Trials Have Sites in Asia Pacific
December 15 2022 10:00 JST
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
December 06 2022 11:00 JST
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
November 11 2022 17:00 JST
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
October 25 2022 18:00 JST
More Press release >>
Latest Press Release
Kirin and Hitachi begin joint research on the creation of forest-based carbon credits
Apr 04, 2025 15:56 JST
Mitsubishi Corporation Announces Corporate Strategy 2027
Apr 04, 2025 09:04 JST
SMBC and Fujitsu partner towards creation of AI-powered data analytics business
Apr 03, 2025 22:10 JST
Prideone Entertainment Announces New Post-War Film to Commemorate the 80th Anniversary of World War II's End
Apr 03, 2025 07:00 JST
"GTF Advantage" Engine Achieved FAA Type Certification
Apr 02, 2025 17:41 JST
Hitachi's New Corporate Vision: Changing the World and Future with the Power of Knowledge
Apr 01, 2025 18:46 JST
Hitachi: Strengthening Our Analytical Business to Solve Social Issues with Our Core Technologies
Apr 01, 2025 18:38 JST
Hitachi: Completion of New Production Facility for Semiconductor Manufacturing Equipment in Kasado Area
Apr 01, 2025 17:52 JST
NEC has developed technologies that enable a secure workflow for personalized cancer vaccines and has proven their capabilities
Apr 01, 2025 16:15 JST
Mitsubishi Motors Launches Miland Virtual Car Lifestyle App Service
Apr 01, 2025 14:59 JST
Mitsubishi Corporation: Development of R&D Hub "iPark Kobe" in Kobe Medical Industry City
Apr 01, 2025 14:16 JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
Apr 01, 2025 13:15 JST
MHIEC Receives Order for Full Refurbishment of Waste Incineration Plant in Itoman City, Okinawa Prefecture
Apr 01, 2025 11:45 JST
MHI Concludes "Mizuho Eco Finance" Commitment Line Agreement
Apr 01, 2025 10:51 JST
MHI Concludes Nissay Positive Impact Finance Agreement
Apr 01, 2025 09:54 JST
Gome Retail Continues to Focus on Its Main Business and Actively Resolve Debt
Apr 01, 2025 02:36 JST
Cryofocus Medtech: Steady Increase in Revenue and Gross Profit with Solid R&D Expenditures in 2024
Apr 01, 2025 01:42 JST
Five NTT Group Companies and Biome Inc. Start Joint Development of Large-scale Estimation Technology for Vegetation and Organisms using Satellite Image Data
Mar 31, 2025 15:43 JST
TANAKA Memorial Foundation Announces Recipients of Precious Metals Research Grants
Mar 31, 2025 11:00 JST
Fujitsu and Macquarie University partner to help address critical shortage of machine learning engineers
Mar 31, 2025 09:28 JST
More Latest Release >>